Breaking News, Collaborations & Alliances

SynCo Bio To Finish OncoMed Phase I Cancer Drug

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

SynCo Bio Partners has signed a master services agreement with OncoMed Pharmaceuticals, under which SynCo will fill and finish batches of OncoMed’s lead product, antibody OMP-21M18, for use in Phase I clinical trials. Pierre Warffemius, SynCo’s chief executive officer, said, “We are delighted that a company at the forefront of cancer therapies has recognized our expertise in biopharmaceutical processing by choosing us to fill their lead antibody for early clinical trails.&#8...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters